In severe pneumonia, which drug can serve as the MRSA-active agent for empiric coverage?

Prepare for the Antibacterials (ABX) Exam. Study with flashcards and multiple-choice questions, each question comes with hints and explanations. Get ready to ace your test!

Multiple Choice

In severe pneumonia, which drug can serve as the MRSA-active agent for empiric coverage?

When a patient presents with severe pneumonia and MRSA could be involved, empiric therapy often includes an antibiotic active against MRSA to prevent treatment delays. Vancomycin fits this role well because it specifically targets MRSA strains and is a standard, widely used option for systemic MRSA coverage in severe infections, including hospital-acquired or ventilator-associated pneumonia. It is typically used alongside coverage for Gram-negative pathogens, which are common in severe pneumonia. Other choices either do not reliably cover MRSA in this setting (ceftriaxone) or have less consistent pneumonia activity or spectrum (doxycycline), while linezolid is also MRSA-active with excellent lung penetration but is not the selected agent in this particular context.

When a patient presents with severe pneumonia and MRSA could be involved, empiric therapy often includes an antibiotic active against MRSA to prevent treatment delays. Vancomycin fits this role well because it specifically targets MRSA strains and is a standard, widely used option for systemic MRSA coverage in severe infections, including hospital-acquired or ventilator-associated pneumonia. It is typically used alongside coverage for Gram-negative pathogens, which are common in severe pneumonia. Other choices either do not reliably cover MRSA in this setting (ceftriaxone) or have less consistent pneumonia activity or spectrum (doxycycline), while linezolid is also MRSA-active with excellent lung penetration but is not the selected agent in this particular context.

More practice questions